Formulation Development
Rein Therapeutics Receives FDA Clearance to Resume Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis
Rein Therapeutics recently announced the US FDA has lifted the full clinical hold on the Company’s Phase 2 “RENEW” trial evaluating LTI-03 in patients with…
Piramal Pharma Solutions Formalizes Partnership With IntoCell, Expanding its Payload-Linker Platform & Bioconjugate Capabilities
Piramal Pharma Solutions has signed a Memorandum of Understanding (MOU) to solidify its strategic partnership and explore potential collaboration opportunities in ADC development with IntoCell Inc.…
4DMT Announces Exclusive License Agreement With Otsuka Pharmaceutical for Development & Commercialization of 4D-150 in Asia-Pacific
4D Molecular Therapeutics recently announced a strategic partnership with Otsuka Pharmaceutical Co., Ltd. (Otsuka) to develop and commercialize 4D-150 for the treatment of wet age-related…
Clearmind Medicine Advances Fight Against Cocaine Addiction With Publication of US Patent Application for its Non-Hallucinogenic Neuroplastogen MEAI Therapy
Clearmind Medicine Inc. recently announced the publication of a US patent application expanding coverage of its non-hallucinogenic proprietary compound, 5-methoxy-2-aminoindane (MEAI), for the treatment of…
Zag Bio Launches With $80 Million Financing to Advance Thymus-Targeted Medicines for Autoimmune Diseases
Zag Bio, Inc. recently announced the company’s launch with $80 million in financing, including a recently closed Series A financing. Polaris Partners founded and incubated Zag…
Slingshot Biosciences & Cellares Combine TruCytes Biomarker Controls With Cell Q Platform to Enhance Quality & Automation in Cell Therapy Manufacturing
Slingshot Biosciences recently announced a strategic collaboration with Cellares that integrates Slingshot’s TruCytes Biomarker controls into Cellares’ Cell Q, the industry’s first fully automated quality-control…
Zenas BioPharma Announces Positive Results From Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis
Zenas BioPharma, Inc. recently announced positive results from the Phase 2 MoonStone trial of obexelimab in Relapsing Multiple Sclerosis (RMS). Obexelimab met the primary endpoint,…
IN8bio Presents T cell Engager Data Demonstrating Deep B Cell Depletion for Autoimmune Indications
IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies for cancer and autoimmune diseases, today presented new preclinical data…
NodThera Announces First Patients Dosed in RESOLVE-2 Clinical Trial Evaluating Oral NT-0796 in Combination With a GLP-1 Receptor Agonist
NodThera, a clinical-stage biotech pioneering a paradigm shift in the treatment of chronic inflammatory diseases through NLRP3 inhibition, today announced that the first patients have…
Curia Invests $4 Million to Enhance Sterile API Manufacturing
Curia Global, Inc. (Curia), a leading global research, development and manufacturing organization, today announced the completion of a $4 million investment to upgrade its two…
Thermo Fisher Scientific Showcases Enhanced Accelerator Drug Development Capabilities & OpenAI Strategic Collaboration at CPHI Frankfurt 2025
Thermo Fisher Scientific Inc., the world leader in serving science, will showcase its latest flexible solutions to help boost efficiency and scale in biopharmaceutical manufacturing…
Serán BioScience Expands Commercial Manufacturing With New Campus in Bend, Oregon
Serán BioScience, LLC, a leading science-driven drug development partner, today announced the completion of two of the three new buildings and commencement of construction of…
Orion & Abzena Announce Exclusive Commercial License for Abzena’s Antibody
Abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, today announced that Orion has obtained an exclusive focused commercial license to one of…
Kindeva Announces the Appointment of David Stevens as President
Kindeva, a global contract development and manufacturing organization (CDMO) and drug delivery innovator, announced the promotion of David Stevens, Chief Operating and Commercial Officer, to…
Vertero Unveils New Strategic Direction Focused on Breaking Barriers in Neurodegenerative Diseases
Axial Therapeutics recently announced it has rebranded as Vertero Therapeutics, a biotechnology company breaking barriers in neurodegenerative disease treatment. The new identity reflects the Company's…
Simcha Therapeutics Presents Preclinical Data Demonstrating Potential for Decoy-Resistant IL-18 to Enhance Efficacy of Bi-specific T-cell Engagers
Simcha Therapeutics, a clinical-stage immunobiology company pioneering first-in-class cytokine treatments for cancer, today announced the presentation of preclinical results which demonstrate enhanced efficacy from combining…
Evonik Launches EUDRACAP Colon Functional Capsules in GMP Quality at CPHI Frankfurt
Evonik’s EUDRACAP colon functional capsules are now available produced under good manufacturing practice (GMP). Launched last year, EUDRACAP colon is the first functional, ready-to-fill capsule…
Roquette Returns to SupplySide Global With New, Unified Vision for Health & Nutrition
Roquette, a global leader in plant-based ingredients, will debut its newly expanded portfolio at SupplySide Global 2025. The event marks the company’s first presentation combining…
Hovione Completes Initial $100M Investment Cycle to Expand US Operations at New Jersey Manufacturing Campus
Hovione, a fully-integrated global CDMO, today announced the completion of an initial multi-million-dollar investment cycle to expand its manufacturing campus in East Windsor, New Jersey.…
XOMA Royalty & LAVA Therapeutics Announce Amendment to Purchase Agreement
XOMA Royalty Corporation and LAVA Therapeutics N.V. recently announced that they have reached an agreement to amend their previously announced definitive share purchase agreement .…
